Norbert Schmitz
Associate Professor
Psychiatry
McGill University
Canada
Biography
Dr. Schmitz is currently a researcher at the Douglas Mental Health University Institute. His research program focuses on three topics in mental health research: 1) Psychiatric epidemiology: research activities involve analyzing data from large national surveys, namely, the longitudinal Canadian National Population Health Survey (NPHS), the Canadian Community Health Surveys (CCHS-1.2, CCHS-2.1, CCHS-3.1), and administrative databases (e.g., Régie de l'Assurance Maladie du Québec's (RAMQ) database). Dr. Schmitz is co-investigator of several prospective community studies focusing on mental health and physical functioning. 2) Psychiatric-somatic co-morbidity: research is concerned with the relationship between mental disorders and somatic chronic conditions. Dr. Schmitz is the principal investigator of the CIHR-funded longitudinal Montreal Diabetes Health and Well-Being Study (DHS). The main focus of this study is on mental health and disability in a representative community sample of people with diabetes in Quebec. 3) Measurement of health status: Dr. Schmitz is interested in the development and application of methods for the assessment of health status (e.g., physical functioning, psychiatric disorders, psychological distress, and health-related quality of life). This includes the evaluation of instruments as well as the development and application of sophisticated psychometric methods to study health outcomes in observational studies and clinical trials (e.g., item response theory, structural regression models, latent class analysis, hierarchical linear models, and classification and regression trees). Applications include the interactions of risk factors for impaired physical and mental functioning.
Research Interest
Population-based studies and clinical trials, diabetes and mental health, epidemiology, psychometrics, biostatistics
Publications
-
Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patients. Pfreundschuh M, Murawski N, Zeynalova S, Ziepert M, Loeffler M, Hänel M, Dierlamm J, Keller U, Dreyling M, Truemper L, Frickhofen N, Hünerlitürkoglu AN, Schmitz N, Pöschel V, Rixecker T, Berdel C, Rübe C, Held G, Zwick C.
-
PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Borchmann P, Goergen H, Kobe C, Lohri A, Greil R, Eichenauer DA, Zijlstra JM, Markova J, Meissner J, Feuring-Buske M, Hüttmann A, Dierlamm J, Soekler M, Beck HJ, Willenbacher W, Ludwig WD, Pabst T, Topp MS, Hitz F, Bentz M, Keller UB, Kühnhardt D, Ostermann H, Schmitz N, Hertenstein B, Aulitzky W, Maschmeyer G, Vieler T, Eich H, Baues C, Stein H, Fuchs M, Kuhnert G, Diehl V, Dietlein M, Engert A.
-
Do mental disorders moderate the association between diabetes status and alcohol consumption? Elgendy R, Deschênes SS, Burns RJ, Schmitz N.
